AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The podcast episode delves into the discussion about the resistance mechanisms to novel targeted agents in acute myeloid leukemia (AML). The experts highlight the puzzling phenomenon of patients with low allelic burden mutations still responding to inhibitors targeting IDH1, IDH2, and FLT3 mutations. It is suggested that non-cell intrinsic effects of the mutant leukemia on other clones, as well as impacts on wild type signaling, may be responsible for these responses. The discussion also explores potential mechanisms such as the role of 2HG in IDH inhibitor response and the impact of wild type FLT3. Additionally, the role of MCL1 and immune modulation in AML treatment is discussed as an important avenue for further development.